Literature DB >> 23950213

Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent.

Maria Elena Martinez1, Betsy C Wertheim, Loki Natarajan, Richard Schwab, Melissa Bondy, Adrian Daneri-Navarro, Maria Mercedes Meza-Montenegro, Luis Enrique Gutierrez-Millan, Abenaa Brewster, Ian K Komenaka, Patricia A Thompson.   

Abstract

BACKGROUND: Published data support the presence of etiologic heterogeneity by breast tumor subtype, but few studies have assessed this in Hispanic populations.
METHODS: We assessed tumor subtype prevalence and associations between reproductive factors and tumor subtypes in 1,041 women of Mexican descent enrolled in a case-only, binational breast cancer study. Multinomial logistic regression comparing HER2(+) tumors and triple-negative breast cancer (TNBC) to luminal A tumors was conducted.
RESULTS: Compared with women with luminal A tumors, those with a later age at first pregnancy were less likely to have TNBC [OR, 0.61; 95% confidence interval (CI), 0.39-0.95], whereas those with three or more full-term pregnancies were more likely to have TNBC (OR, 1.68; 95% CI, 1.10-2.55). A lower odds of TNBC was shown for longer menstruation duration, whether before first pregnancy (OR, 0.78; 95% CI, 0.65-0.93 per 10 years) or menopause (OR, 0.79; 95% CI, 0.69-0.91 per 10 years). Patients who reported breastfeeding for more than 12 months were over twice as likely to have TNBC than luminal A tumors (OR, 2.14; 95% CI, 1.24-3.68). Associations comparing HER2(+) with luminal A tumors were weak or nonexistent except for the interval between last full-term pregnancy and breast cancer diagnosis.
CONCLUSIONS: Findings show etiologic heterogeneity by tumor subtype in a population of Hispanic women with unique reproductive profiles. IMPACT: Identification of etiologically distinct breast tumor subtypes can further improve our understanding of the disease and help provide personalized prevention and treatment regimens.

Entities:  

Mesh:

Year:  2013        PMID: 23950213      PMCID: PMC3799795          DOI: 10.1158/1055-9965.EPI-13-0560

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  35 in total

Review 1.  Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.

Authors:  M Dowsett
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

2.  Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women.

Authors:  F Clavel-Chapelon
Journal:  Cancer Causes Control       Date:  2002-11       Impact factor: 2.506

Review 3.  Endocrine aspects of cancer: an epidemiological approach.

Authors:  F De Waard
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

Review 4.  Epidemiology of breast cancer.

Authors:  T J Key; P K Verkasalo; E Banks
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

Review 5.  Cellular basis of breast cancer susceptibility.

Authors:  J Russo; I H Russo
Journal:  Oncol Res       Date:  1999       Impact factor: 5.574

6.  Postmenopausal breast cancer risk and cumulative number of menstrual cycles.

Authors:  Mariana Chavez-MacGregor; Sjoerd G Elias; N Charlotte Onland-Moret; Yvonne T van der Schouw; Carla H Van Gils; Evelyn Monninkhof; Diederick E Grobbee; Petra H M Peeters
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

Review 7.  Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

Authors:  Mariaelena Pierobon; Cara L Frankenfeld
Journal:  Breast Cancer Res Treat       Date:  2012-11-20       Impact factor: 4.872

8.  Differences in breast cancer stage, treatment, and survival by race and ethnicity.

Authors:  Christopher I Li; Kathleen E Malone; Janet R Daling
Journal:  Arch Intern Med       Date:  2003-01-13

9.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies.

Authors:  Huiyan Ma; Leslie Bernstein; Malcolm C Pike; Giske Ursin
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease.

Authors: 
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

View more
  27 in total

1.  Heterogeneous Associations Between Obesity and Reproductive-Related Factors and Specific Breast Cancer Subtypes Among Hong Kong Chinese Women.

Authors:  Priscilla Ming Yi Lee; Chi Hei Kwok; Wing Cheong Chan; Cherry Wu; Koon-Ho Tsang; Sze-Hong Law; Yiu-Cheong Yeung; Feng Wang; Xiaohong R Yang; Lap Ah Tse
Journal:  Horm Cancer       Date:  2020-06-03       Impact factor: 3.869

Review 2.  Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Authors:  Jaime Fornetti; Holly A Martinson; Courtney B Betts; Traci R Lyons; Sonali Jindal; Qiuchen Guo; Lisa M Coussens; Virginia F Borges; Pepper Schedin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-06-22       Impact factor: 2.673

3.  Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution.

Authors:  Ian K Komenaka; Jesse N Nodora; Lisa Madlensky; Lisa M Winton; Meredith A Heberer; Richard B Schwab; Jeffrey N Weitzel; Maria Elena Martinez
Journal:  J Community Genet       Date:  2015-12-21

4.  Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.

Authors:  Melanie Ruszczyk; Gary Zirpoli; Shicha Kumar; Elisa V Bandera; Dana H Bovbjerg; Lina Jandorf; Thaer Khoury; Helena Hwang; Gregory Ciupak; Karen Pawlish; Pepper Schedin; Patricia Masso-Welch; Christine B Ambrosone; Chi-Chen Hong
Journal:  Cancer Causes Control       Date:  2015-11-30       Impact factor: 2.506

5.  Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.

Authors:  Lu Chen; Christopher I Li; Mei-Tzu C Tang; Peggy Porter; Deirdre A Hill; Charles L Wiggins; Linda S Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-06-15       Impact factor: 4.254

6.  Associations between estrogen receptor-negative breast cancer and timing of reproductive events differ between African American and European American women.

Authors:  Christine B Ambrosone; Gary R Zirpoli; Dana Howard Bovbjerg; Jyoti Shankar; Chi-Chen Hong; Susan E McCann; Melanie Ruszczyk; Thaer Khoury; Song Yao; Gregory L Ciupak; Lina Jandorf; Karen S Pawlish; Elisa V Bandera
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-09       Impact factor: 4.254

Review 7.  Reproductive risk factors and breast cancer subtypes: a review of the literature.

Authors:  Kristin N Anderson; Richard B Schwab; Maria Elena Martinez
Journal:  Breast Cancer Res Treat       Date:  2014-01-30       Impact factor: 4.872

Review 8.  Breast Cancer in Latinas: A Focus on Intrinsic Subtypes Distribution.

Authors:  Silvia J Serrano-Gómez; Laura Fejerman; Jovanny Zabaleta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-10-20       Impact factor: 4.254

9.  Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.

Authors:  Julie R Palmer; Emma Viscidi; Melissa A Troester; Chi-Chen Hong; Pepper Schedin; Traci N Bethea; Elisa V Bandera; Virginia Borges; Craig McKinnon; Christopher A Haiman; Kathryn Lunetta; Laurence N Kolonel; Lynn Rosenberg; Andrew F Olshan; Christine B Ambrosone
Journal:  J Natl Cancer Inst       Date:  2014-09-15       Impact factor: 13.506

10.  Divergent breast cancer incidence trends by hormone receptor status in the state of Sarawak, Malaysia.

Authors:  Hyuna Sung; Beena C R Devi; Tieng S Tang; Philip S Rosenberg; William F Anderson; Xiaohong R Yang
Journal:  Int J Cancer       Date:  2019-12-23       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.